z-logo
open-access-imgOpen Access
Neuropathological Findings in Intractable Epilepsy: 435 Chinese Cases
Author(s) -
Piao YueShan,
Lu DeHong,
Chen Li,
Liu Jing,
Wang Wei,
Liu Lei,
Yu Tao,
Wang YuPing,
Li YongJie
Publication year - 2010
Publication title -
brain pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.986
H-Index - 132
eISSN - 1750-3639
pISSN - 1015-6305
DOI - 10.1111/j.1750-3639.2010.00386.x
Subject(s) - cortical dysplasia , ganglioglioma , neuropathology , hippocampal sclerosis , epilepsy , temporal lobe , intractable epilepsy , medicine , pathology , abnormality , frontal lobe , epilepsy surgery , disease , psychiatry
The number of patients with intractable epilepsy undergoing surgical management in China is increasing rapidly. We retrospectively reviewed 435 consecutive cases of intractable epilepsy receiving surgical resection from 2005 to 2008 in our hospital, looking specifically at the neuropathological findings. The three most common causes of intractable epilepsy were focal cortical dysplasia (FCD; 52.9%), scar lesions (22.8%) and brain tumors (11.7%). Hippocampal sclerosis was identified in 74 cases (17.0%), although most of these were accompanied by dual pathology with FCD (especially Palmini type IB), scar lesions or tumors. Among FCD cases, Palmini type I lesions are the most frequently observed abnormality, with a preferred location in the temporal lobe (60.1%) and often accompanied by dual pathology. In contrast, Palmini type II FCD lesions occurred predominantly in the frontal regions and with a lower age of onset. Most tumors were mixed neuronal–glial tumors, mainly ganglioglioma (19 cases) and dysembryoplastic neuroepithelial tumor (10 cases), with a trend toward a temporal location and usually accompanied by cortical dysplasia in the peritumor area. Our data on the neuropathology of intractable epilepsy in China show that glioneuronal lesions are the most prominent cause of intractable epilepsy, and this is consistent with reports from other countries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here